Summary of Study ST003256

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002015. The data can be accessed directly via it's Project DOI: 10.21228/M85238 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST003256
Study Title	Exploration of Zeb1-dependent changes in the redox-lipidome of MDA-MB-231 cells
Study Summary	Human breast cancer MDA-MB-231 wildtype (WT) cells and the stably transduced MDA-MB-231 shZeb1 (stable Zeb1 knockdown) and shCtrl cell lines (control cell line for the stable Zeb1 knockdown) (Spaderna et al. 2008, DOI: 10.1158/0008-5472.CAN-07-5682) were treated with DMSO or RSL3 (1 or 10 µM) for 2 h, 4 h, 6 h or 24 h. The cell pellets were collected and analyzed for their oxidized phospholipid profile by UPLC-MS/MS. Please note that one sample set was measured three times with the same sample-ID, but with different methods (Ox-PE, Ox-PC, Ox-PI), therefore each sub-class has their own raw-data file marked by their corresponding abbreviation (Ox-PE, Ox-PC, Ox-PI; e.g. "210514_MDA_ZEB1_oxPE_dil_UD_std_1ul_JZ_oxPE_MRM_003.wiff", "210514_MDA_ZEB1_oxPC_dil_UD_std_1ul_JZ_oxPC_MRM_002.wiff" or "210514_MDA_ZEB1_oxPI_dil_UD_std_1ul_JZ_oxPI_MRM_001.wiff").
Institute	University of Innsbruck
Department	Michael Popp Institute
Last Name	Koeberle
First Name	Andreas
Address	Mitterweg 24, Innsbruck, Tyrol, 6020, Austria
Email	Andreas.Koeberle@uibk.ac.at
Phone	+43 512 507 57903
Submit Date	2024-05-27
Raw Data Available	Yes
Raw Data File Type(s)	wiff
Analysis Type Detail	LC-MS
Release Date	2024-07-05
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR003384
Treatment Summary:	Brest cancer cells (MDA-MB-231 cells) for oxPE, oxPC, oxPI: Human breast cancer MDA-MB-231 wildtype (WT) cells and the stably transduced MDA-MB-231 shZeb1 (stable Zeb1 knockdown) and shCtrl cell lines (control cell line for the stable Zeb1 knockdown) (Spaderna et al. 2008, DOI: 10.1158/0008-5472.CAN-07-5682) were treated with vehicle (DMSO) or RSL3 (1 and 10 µM) for 2 h, 4 h, 6 h, 24 h or 48 h at 37°C and 5% CO2.

Treatment ID:

TR003384

Treatment Summary:

Brest cancer cells (MDA-MB-231 cells) for oxPE, oxPC, oxPI: Human breast cancer MDA-MB-231 wildtype (WT) cells and the stably transduced MDA-MB-231 shZeb1 (stable Zeb1 knockdown) and shCtrl cell lines (control cell line for the stable Zeb1 knockdown) (Spaderna et al. 2008, DOI: 10.1158/0008-5472.CAN-07-5682) were treated with vehicle (DMSO) or RSL3 (1 and 10 µM) for 2 h, 4 h, 6 h, 24 h or 48 h at 37°C and 5% CO2.